Insight Molecular Diagnostics Inc. current report, 02 April 2018

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on April 2, 2018. The filing addresses corporate governance changes, specifically the appointment of a new director to fill a vacancy on the Board of Directors.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and compensation arrangements rather than financial performance.

Material Changes

The material change reported is the appointment of Ronald A. Andrews, Jr. to the Board of Directors effective April 2, 2018. Mr. Andrews will serve on the Audit Committee and the Science & Technology Committee and will act as Chair of the Compensation Committee.

Guidance, Outlook, and Management Commentary

The filing includes standard forward-looking statement disclaimers, noting that actual results may differ from anticipated results due to risk factors detailed in the company's Form 10. There is no specific business outlook or guidance provided in this document. The filing details the compensatory arrangements for the new director, which include:

  • Annual cash fee of $30,000 for director service.
  • Options to purchase 20,000 shares of common stock.
  • Annual cash fee of $7,500 for Audit Committee service.
  • Annual cash fee of $5,000 for Science & Technology Committee service.
  • Annual cash fee of $10,000 for Chair of the Compensation Committee.

Compensation vests in four equal quarterly installments contingent on continued service.

Investor Verification Checklist

  • Verify the correct registrant name is OncoCyte Corporation, not Insight Molecular Diagnostics Inc.
  • Confirm the vesting schedule and expiration terms of the 20,000 stock options granted to the new director.
  • Review the company's Form 10 for detailed risk factors referenced in the forward-looking statements.
  • Check subsequent filings to confirm Mr. Andrews' continued service and any changes to committee assignments.